Oruka Therapeutics (HQ1) Price & Analysis

0 Followers

HQ1 Stock Chart & Stats

€78.00

€1.00(1.30%)

At close: Jul 30 4:00 PM EDT

€78.00

€1.00(1.30%)

Day’s Range― - ―

52-Week Range€12.30 - €96.50

Previous CloseN/A

Volume34.00

Average Volume (3M)12.00

Market Cap

€5.21B

Enterprise Value€5.12K

Total Cash (Recent Filing)€873.56M

Total Debt (Recent Filing)€2.55M

Price to Earnings (P/E)―

Beta0.12

Next Earnings

Nov 18, 2026

EPS Estimate

-0.5

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.47

Shares Outstanding66,209,700

10 Day Avg. Volume7

30 Day Avg. Volume12

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)2.93

Price to Sales (P/S)0.00

P/FCF Ratio-15.64

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€134.99

Price Target Upside73.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-1.99

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong, Low-debt Balance SheetMinimal leverage and a substantially expanded capital base provide financial flexibility for clinical development. This reduces near-term balance-sheet risk and gives Oruka more capacity to fund programs or pursue partnerships.

Experienced Commercial Leadership AddedHiring a dermatology and immunology commercialization veteran strengthens preparation for potential product launches. It may improve future market-access, launch-planning and partnering capabilities as clinical assets advance.

Broader IL-23 License ScopeA broader licensed field increases the potential applications and strategic flexibility of the IL-23 platform, including ORKA-001. This could support development optionality and future partnering across multiple indications.

Bears Say

Pre-revenue Business ModelOruka has no recurring product revenue because its therapies remain in clinical development. Until commercialization or partnering inflows emerge, the company lacks an operating revenue base to offset research, development and corporate costs.

Widening Operating And Net LossesExpanding losses indicate that development spending is increasing ahead of any commercial return. Continued deterioration in profitability can pressure capital efficiency and raise the funding required before clinical assets generate meaningful economic value.

Accelerating Cash BurnThe worsening cash outflow increases dependence on future financing, equity issuance or partnering proceeds. Even with low debt, sustained clinical spending could reduce financial flexibility if programs take longer to advance or monetization is delayed.

Oruka Therapeutics News

Oruka Therapeutics appoints Todd Edwards as chief commercial officer

Oruka Therapeutics (ORKA) announced the appointment of Todd Edwards as chief commercial officer, effective August 24. Edwards joins...

6d ago

ARQT

ORKA

Oruka Therapeutics files $1B mixed securities shelf

16:20 EDT Oruka Therapeutics (ORKA) files $1B mixed securities shelf Published first on TheFly – the ultimate source...

9d ago

ORKA

Oruka Therapeutics reports Q2 EPS (55c), consensus (50c)

“The second quarter and recent months were highly productive as we advanced both of our co-lead programs toward...

20d ago

ORKA

Tyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ORKA stock, giving a Buy rating...

4d ago

ORKA

Oruka Therapeutics Appoints Todd Edwards Chief Commercial Officer

Oruka Therapeutics ( ($ORKA) ) has issued an announcement. On July 22, 2026, Oruka Therapeutics appointed veteran commercial...

6d ago

ORKA

Oruka Therapeutics: Strong Clinical Momentum and Pipeline Optionality Support Buy Rating and Unchanged $151 Price Target

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Oruka Therapeutics, with a...

19d ago

ORKA

Oruka Therapeutics: Buy Rating Reaffirmed as EVERLAST-A Data Support Once-Yearly ORKA-001; $120 Price Target Maintained

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Oruka Therapeutics today and set a price target...

27d ago

ORKA

Oruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Oruka Therapeutics today and set a price target...

1M ago

ORKA

3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts

Healthcare remains one of the market’s most steady sectors this year, backed by biotech innovation and medical device...

2M ago

BSX

INSM

Oruka Therapeutics falls -8.1%

Oruka Therapeutics (ORKA) is down -8.1%, or -$7.60 to $85.69. Published first on TheFly – the ultimate source...

2M ago

ORKA

Oruka Therapeutics price target raised to $130 from $100 at UBS

UBS raised the firm’s price target on Oruka Therapeutics (ORKA) to $130 from $100 and keeps a Buy...

2M ago

ORKA

BTIG says others may be interested in Apogee Therapeutics

BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis...

2M ago

JNJ

NVS

Oruka Therapeutics Shareholders Back Governance and Executive Pay

Oruka Therapeutics ( ($ORKA) ) has issued an update. At its June 2, 2026 annual meeting, Oruka Therapeutics...

3M ago

ORKA

Kapoor Reiterates Buy on Oruka Therapeutics as Pipeline Advances; Keeps $120 Price Target Unchanged

H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on ORKA stock, giving a Buy rating yesterday....

3M ago

ORKA

HQ1 FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was €12.30 and its highest was €96.50 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is €5.21B.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 80 days.

How were Oruka Therapeutics’s earnings last quarter?

Oruka Therapeutics released its earnings results on Aug 10, 2026. The company reported -€0.471 earnings per share for the quarter, missing the consensus estimate of -€0.439 by -€0.033.

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics does not currently pay dividends.

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate is -0.5.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 66,209,700 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Oruka Therapeutics reported an EPS of -€0.471 in its last earnings report, missing expectations of -€0.439. Following the earnings report the stock price went up 2.367%.

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in DE:HQ1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oruka Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

218.78%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics (HQ1) Earnings & Revenues

Historic Earnings Reports

HQ1 Stock 12 Month Forecast

Average Price Target

€134.99

▲(73.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","173":"€173","50.75":"€50.8","91.5":"€91.5","132.25":"€132.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":172.62079,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€172.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":134.98945778,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€134.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103.572474,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€103.57</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,50.75,91.5,132.25,173],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,91.74006076923077,98.48012153846153,105.22018230769231,111.96024307692308,118.70030384615384,125.44036461538462,132.18042538461538,138.92048615384616,145.66054692307694,152.4006076923077,159.14066846153847,165.88072923076925,{"y":172.62079,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,88.84534290615385,92.69068581230769,96.53602871846154,100.38137162461538,104.22671453076923,108.07205743692307,111.91740034307693,115.76274324923077,119.60808615538463,123.45342906153846,127.29877196769232,131.14411487384615,{"y":134.98945778,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85,86.42865184615384,87.8573036923077,89.28595553846154,90.71460738461539,92.14325923076923,93.57191107692307,95.00056292307693,96.42921476923077,97.85786661538461,99.28651846153846,100.7151703076923,102.14382215384616,{"y":103.572474,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >